secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zoetis Inc. (ZTS)
CIK:        0001555280
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0001555280-24-000141
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zoetis Q4 2023 revenue $2.2B (+8%), adj. EPS $1.24; FY2024 guidance $9.075-9.225B
--------------------------------------------------------------------------------

- Q4 revenue $2.2B (+8% reported & operational); net income $525M ($1.14 diluted EPS), up 14% and 15% respectively.
- Adjusted net income Q4 $569M ($1.24 diluted EPS), up 6% operational.
- FY 2023 revenue $8.5B (+6% reported, +7% operational); net income $2.3B ($5.07 diluted EPS).
- FY 2024 guidance: revenue $9.075-9.225B (operational growth 7-9%); adjusted diluted EPS $5.74-5.84.
- Key growth drivers: Librela, Simparica Trio, dermatology; new approvals for Solensia in Brazil and Simparica Trio in China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1555280/000155528024000141/0001555280-24-000141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1555280/000155528024000141/zts-20240213.htm
  HTML page:      https://secwatch.observer/filing/0001555280-24-000141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer